



22 OCTOBER, 2022
(SATURDAY)



08:30 - 16:00 HRS
UAE TIME



HYBRID
(IN-PERSON & VIRTUAL)



AL RAS 2

SESSION 1

- Chairperson:** Rham Zaki Ahmed, UAE | Aydah Al Awadhi, UAE
- 08:30 - 08:45 **Opening Remarks**
Shaheenah Dawood, UAE
- 08:45 - 09:05 What Changed Practice and What Didn't?
Stephen Johnston, United Kingdom
- 09:05 - 09:20 Fertility and Breast Cancer in 2022
Tanya Buckshee Rohatgi, India
- 09:20 - 09:40 HR+HER2- Advanced Breast Cancer: How the latest data can help inform treatment decision -
Supported by Novartis
Mohsen Mokhtar, Egypt
- 09:40 - 10:20 Tumor Board Discussion: Challenging Cases for Metastatic HR+ve Breast Cancer
Moderator: Hamdy Abdul Azim, Egypt
Panel: Stephen Johnston, United Kingdom | Javier Cortes, Spain | Nitesh Rohatgi, India | Zulfaqqar Jaffar, UAE | Mohsen Mokhtar, Egypt | Sonia Otsmane, UAE | Ramanujam Singarachari, UAE
- 10:20 - 10:40 Abemaciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-positive, High-risk Early Breast Cancer - *Supported by Lilly*
Sonia Otsmane, UAE

10:40 - 11:00 **Coffee Break**

SESSION 2

- Chairperson:** Ankur Bahl, India | Diaeddine Trad, UAE
- 11:00 - 11:15 Recent Clinical Advancement in HER2+ mBC Setting - *Supported by AstraZeneca*
Shaheenah Dawood, UAE
- 11:15 - 11:30 Sequencing in ER Positive Her 2 Low MBC
Shanu Modi, USA
- 11:30 - 11:45 Molecular Testing in Metastatic Breast Cancer: Should It Be Standard of Care In 2022?
Javier Cortes, Spain
- 11:45 - 12:05 mTNBC Treatment Challenges & Treatment Evolution - *Supported by Gilead*
Mark Verrill, United Kingdom
- 12:05 - 12:35 Tumor Board: Challenging Cases for Metastatic TNBC and HER2 Positive Breast Cancer
Moderator: Mohsen Mokhtar, Egypt
Panel: Zulfaqqar Jaffar, UAE | Nisar Syed, India | Ahmed Saadeddin, KSA | Fathi Azribi, UAE | Sonia Otsmane, UAE | Nitesh Rohatgi, India

12:35 - 12:40 **Q & A**

12:40 - 13:00 Modern Cancer Care for Modern Cancer Treatments: Optimal Emesis Prevention for Today's Treatment Options - **Supported by Juniper Biologics**
Sandeep Sehdev, Canada

13:00 - 14:00 **Lunch Break**

SESSION 3

Chairperson: Nita Nair, India | Mouza Al Ameri, UAE

14:00 - 14:15 Panel Discussion: Local Treatment Landscape for HER2+ Breast Cancer - **Supported by Roche**
Moderator: Shaheenah Dawood, UAE
Panel: Maroun El Khoury, UAE | Diaeddine Trad, UAE | Nouri Bennini, UAE | Sonia Otsmane, UAE

14:15 - 14:30 Optimizing Adjuvant Endocrine Therapy
Stephen Johnston, United Kingdom

14:30 - 14:45 Improving Surgical Cure in Early Breast Cancer
Rajendra Badwe, India

14:45 - 15:05 Real world Effectiveness data in HR+ /HER2- Metastatic Breast Cancer - **Supported by Pfizer**
Anwar AlNouri, Kuwait

15:05 - 15:35 Challenging Cases in Early-Stage Breast Cancer
Moderator: Nitesh Rohatgi, India
Panel: Stephen Johnston, United Kingdom | Javier Cortes, Spain | Ankur Bahl, India | Nita Nair, India | Javid Muzamil, India | Nouri Bennini, UAE | Emad Anwar Dawoud, UAE

15:35 - 15:55 Role of GnRH agonist in High Risk HR+ Early Stage Breast Cancer - **Supported by IPSEN**
Chairperson: Emad Anwar Dawoud, UAE
Speaker: Olivia Pagani, Switzerland

15:55 - 16:00 **Closing Remarks**